Intrinsic resistance to chemotherapy in breast cancer

Women's Health

Volumn 6, Issue 6, 2010, Pages 821-830

  Moulder, Stacy ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

adjuvant therapy; biologic therapy; breast cancer; intrinsic resistance; metastatic disease; targeted therapy

Indexed keywords

ANTHRACYCLINE DERIVATIVE; CYCLOSPORIN; DNA TOPOISOMERASE (ATP HYDROLYSING); EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; ESTROGEN RECEPTOR; EVEROLIMUS; FLUOROURACIL; GLYCOPROTEIN P; LETROZOLE; PROTEIN BCL 2; QUINIDINE; TARIQUIDAR; TAXANE DERIVATIVE; TRASTUZUMAB; VALSPODAR; VERAPAMIL; VINDESINE; ZOSUQUIDAR;

ADJUVANT THERAPY; ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER RESISTANCE; CANCER STAGING; CANCER STEM CELL; CANCER SURGERY; CANCER SURVIVAL; CELL LEVEL; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG TARGETING; FEMALE; HUMAN; LYMPH NODE METASTASIS; MALIGNANT TRANSFORMATION; MASTECTOMY; NONHUMAN; PRIMARY TUMOR; PROTEIN EXPRESSION; REVIEW; RISK REDUCTION; SYSTEMIC THERAPY; TREATMENT INDICATION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; NEOPLASM STAGING; P-GLYCOPROTEIN; TREATMENT FAILURE;

EID: 78649927335     PISSN: 17455057     EISSN: 17455065     Source Type: Journal    
DOI: 10.2217/whe.10.60     Document Type: Review

References (89)

1. Early Breast Cancer Trialists Collaborative Group (EBCTCG): Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365, 1687-1717 (2005).
2. Goldie JH: Drug resistance and cancer chemotherapy strategy in breast cancer. Breast Cancer Res. Treat. 3, 129-136 (1983).
3. Slamon DJ, Leyland-Jones B, Shak S et al.: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 344, 783-792 (2001).
4. Romond EH, Perez EA, Bryant J et al.: Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N. Engl. J. Med. 353, 1673-1684 (2005).
5. Piccart-Gebhart MJ, Procter M, Leyland-Jones B et al.: Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N. Engl. J. Med. 353, 1659-1672 (2005).
6. Miller K, Wang M, Gralow J et al.: Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N. Engl. J. Med. 357, 2666-2676 (2007).
7. Polychemotherapy for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists Collaborative Group. Lancet 352, 930-942 (1998).
8. Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists Collaborative Group. Lancet 351, 1451-1467 (1998).
9. Mauriac L, Durand M, Avril A, Dilhuydy JM: Effects of primary chemotherapy in conservative treatment of breast cancer patients with operable tumors larger than 3 cm. Results of a randomized trial in a single centre. Ann. Oncol. 2, 347-354 (1991).
10. Perloff M, Lesnick GJ, Korzun A et al.: Combination chemotherapy with mastectomy or radiotherapy for stage III breast carcinoma: a Cancer and Leukemia Group B study. J. Clin. Oncol. 6, 261-269 (1988).
11. Greenberg PA, Hortobagyi GN, Smith TL, Ziegler LD, Frye DK, Buzdar AU: Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer. J. Clin. Oncol. 14, 2197-2205 (1996).
12. Buzdar AU, Hortobagyi G: Update on endocrine therapy for breast cancer. Clin. Cancer Res. 4, 527-534 (1998). (Pubitemid 28193549)
13. Duffy MJ: Predictive markers in breast and other cancers: a review. Clin. Chem. 51, 494-503 (2005).
14. Mittendorf EA, Wu Y, Scaltriti M et al.: Loss of HER2 amplification following trastuzumab-based neoadjuvant systemic therapy and survival outcomes. Clin. Cancer Res. 15, 7381-7388 (2009).
15. Liedtke C, Broglio K, Moulder S et al.: Prognostic impact of discordance between triple-receptor measurements in primary and recurrent breast cancer. Ann. Oncol. 20, 1953-1958 (2009).
16. Nitiss JL, Beck WT: Antitopoisomerase drug action and resistance. Eur. J. Cancer 32A, 958-966 (1996).
17. Miller ML, Ojima I: Chemistry and chemical biology of taxane anticancer agents. Chem. Rec. 1, 195-211 (2001).
18. Oakman C, Moretti E, Galardi F, Santarpia L, Di Leo A: The role of topoisomerase IIa and HER-2 in predicting sensitivity to anthracyclines in breast cancer patients. Cancer Treat. Rev. 35(8), 662-667(2009).
19. Houlbrook S, Addison CM, Davies SL et al.: Relationship between expression of topoisomerase II isoforms and intrinsic sensitivity to topoisomerase II inhibitors in breast cancer cell lines. Br. J. Cancer 72, 1454-1461 (1995).
20. Klumper E, Giaccone G, Pieters R et al.: Topoisomerase II a gene expression in childhood acute lymphoblastic leukemia. Leukemia 9, 1653-1660 (1995).
21. Kaufmann SH, Karp JE, Jones RJ et al.: Topoisomerase II levels and drug sensitivity in adult acute myelogenous leukemia. Blood 83, 517-530 (1994).
22. Kavallaris M, Kuo DY, Burkhart CA et al.: Taxol-resistant epithelial ovarian tumors are associated with altered expression of specific b-tubulin isotypes. J. Clin. Invest. 100, 1282-1293 (1997).
23. Dumontet C, Jordan MA, Lee FF: Ixabepilone: targeting bIII-tubulin expression in taxane-resistant malignancies. Mol. Cancer Ther. 8, 17-25 (2009).
24. Hasegawa S, Miyoshi Y, Egawa C et al.: Prediction of response to docetaxel by quantitative analysis of class I and III b-tubulin isotype mRNA expression in human breast cancers. Clin. Cancer Res. 9, 2992-2997 (2003).
25. Bernard-Marty C, Treilleux I, Dumontet C et al.: Microtubule-associated parameters as predictive markers of docetaxel activity in advanced breast cancer patients: results of a pilot study. Clin. Breast Cancer 3, 341-345 (2002).
26. Dean M, Hamon Y, Chimini G: The human ATP-binding cassette (ABC) transporter superfamily. J. Lipid Res. 42, 1007-1017 (2001). (Pubitemid 32645780)
27. Szakacs G, Paterson JK, Ludwig JA, Booth-Genthe C, Gottesman MM: Targeting multidrug resistance in cancer. Nat. Rev. Drug Discov. 5, 219-234 (2006).
28. Dean M, Rzhetsky A, Allikmets R: The human ATP-binding cassette (ABC) transporter superfamily. Genome Res. 11, 1156-1166 (2001). (Pubitemid 32677289)
29. Ambudkar SV, Dey S, Hrycyna CA, Ramachandra M, Pastan I, Gottesman MM: Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annu. Rev. Pharmacol. Toxicol. 39, 361-398 (1999).
30. Gottesman MM, Fojo T, Bates SE: Multidrug resistance in cancer: role of ATP-dependent transporters. Nat. Rev. Cancer 2, 48-58 (2002).
31. Clarke R, Leonessa F, Trock B: Multidrug resistance/P-glycoprotein and breast cancer: review and meta-analysis. Semin. Oncol. 32, S9-S15 (2005).
32. Trock BJ, Leonessa F, Clarke R: Multidrug resistance in breast cancer: a meta-analysis of MDR1/gp170 expression and its possible functional significance. J. Natl Cancer Inst. 89, 917-931 (1997).
33. Oltersdorf T, Elmore SW, Shoemaker AR et al.: An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 435, 677-681 (2005).
34. Reed JC: Regulation of apoptosis by bcl-2 family proteins and its role in cancer and chemoresistance. Curr. Opin. Oncol. 7, 541-546 (1995).
35. Armstrong JS: The role of the mitochondrial permeability transition in cell death. Mitochondrion 6(5), 225-234 (2006).
36. Benimetskaya L, Ayyanar K, Kornblum N et al.: Bcl-2 protein in 518A2 melanoma cells in vivo and in vitro. Clin. Cancer Res. 12, 4940-4948 (2006).
37. Kim R, Emi M, Tanabe K, Toge T: Therapeutic potential of antisense bcl-2 as a chemosensitizer for patienst with gastric carcinoma. Presented at: 2005 American Society of Clinical Oncology Annual Meeting. Orlando, FL, USA, 13-17 May (2005).
38. Gasparini G, Barbareschi M, Doglioni C et al.: Expression of Bcl-2 protein predicts efficacy of adjuvant treatments in operable node-positive breast cancer. Clin. Cancer Res. 1, 189-198 (1995).
39. Gee JM, Robertson JF, Ellis IO et al.: Immunocytochemical localization of Bcl-2 protein in human breast cancers and its relationship to a series of prognostic markers and response to endocrine therapy. Int. J. Cancer 59, 619-628 (1994).
40. Hellemans P, van Dam PA, Weyler J, van Oosterom AT, Buytaert P, Van Marck E: Prognostic value of bcl-2 expression in invasive breast cancer. Br. J. Cancer 72, 354-360 (1995).
41. Joensuu H, Pylkkanen L, Toikkanen S: Bcl-2 protein expression and long-term survival in breast cancer. Am. J. Pathol. 145, 1191-1198 (1994).
42. Bonetti A, Zaninelli M, Leone R et al.: bcl-2 but not p53 expression is associated with resistance to chemotherapy in advanced breast cancer. Clin. Cancer Res. 4, 2331-2336 (1998).
43. Buchholz TA, Davis DW, McConkey DJ et al.: Chemotherapy-induced apoptosis and Bcl-2 levels correlate with breast cancer response to chemotherapy. Cancer J. 9, 33-41 (2003).
44. Chi KC, Wallis AE, Lee CH et al.: Effects of Bcl-2 modulation with G3139 antisense oligonucleotide on human breast cancer cells are independent of inherent Bcl-2 protein expression. Breast Cancer Res. Treat. 63, 199-212 (2000).
45. Burz C, Berindan-Neagoe I, Balacescu O, Irimie A: Apoptosis in cancer: key molecular signaling pathways and therapy targets. Acta Oncol. 48, 811-821 (2009).
46. Carraway H, Hidalgo M: New targets for therapy in breast cancer: mammalian target of rapamycin (mTOR) antagonists. Breast Cancer Res. 6, 219-224 (2004).
47. Sarbassov DD, Guertin DA, Ali SM, Sabatini DM: Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 307, 1098-1101 (2005).
48. Datta SR, Dudek H, Tao X et al.: Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 91, 231-241 (1997).
49. Shimamura H, Terada Y, Okado T, Tanaka H, Inoshita S, Sasaki S: The PI3-kinase-Akt pathway promotes mesangial cell survival and inhibits apoptosis in vitro via NF-kB and Bad. J. Am. Soc. Nephrol. 14, 1427-1434 (2003).
50. Cantley LC, Neel BG: New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway. Proc. Natl Acad. Sci. USA 96, 4240-4245 (1999).
51. Holbro T, Beerli RR, Maurer F, Koziczak M, Barbas CF 3rd, Hynes NE: The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation. Proc. Natl Acad. Sci. USA 100, 8933-8938 (2003).
52. Bachman KE, Argani P, Samuels Y et al.: The PIK3CA gene is mutated with high frequency in human breast cancers. Cancer Biol. Ther. 3, 772-775 (2004). (Pubitemid 41351083)
53. Kang S, Bader AG, Vogt PK: Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic. Proc. Natl Acad. Sci. USA 102, 802-807 (2005).
54. McCubrey JA, Steelman LS, Abrams SL et al.: Roles of the RAF/MEK/ERK and PI3K/ PTEN/AKT pathways in malignant transformation and drug resistance. Adv. Enzyme Regul. 46, 249-279 (2006).
55. Lee JT, Steelman LS, Chappell WH, McCubrey JA: Akt inactivates ERK causing decreased response to chemotherapeutic drugs in advanced CaP cells. Cell Cycle 7, 631-636 (2008).
56. Clark AS, West K, Streicher S, Dennis PA: Constitutive and inducible Akt activitypromotes resistance to chemotherapy, trastuzumab, or tamoxifen in breast cancer cells. Mol. Cancer Ther. 1, 707-717 (2002).
57. Shoman N, Klassen S, McFadden A, Bickis MG, Torlakovic E, Chibbar R: Reduced PTEN expression predicts relapse in patients with breast carcinoma treated by tamoxifen. Mod. Pathol. 18, 250-259 (2005).
58. Nagata Y, Lan KH, Zhou X et al.: PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 6, 117-127 (2004).
59. Perez-Tenorio G, Stal O: Activation of AKT/ PKB in breast cancer predicts a worse outcome among endocrine treated patients. Br. J. Cancer 86, 540-545 (2002).
60. Perren A, Weng LP, Boag AH et al.: Immunohistochemical evidence of loss of PTEN expression in primary ductal adenocarcinomas of the breast. Am. J. Pathol. 155, 1253-1260 (1999).
61. Tsutsui S, Inoue H, Yasuda K et al.: Reduced expression of PTEN protein and its prognostic implications in invasive ductal carcinoma of the breast. Oncology 68, 398-404 (2005).
62. Ullrich A, Bell JR, Chen EY et al.: Human insulin receptor and its relationship to the tyrosine kinase family of oncogenes. Nature 313, 756-761 (1985).
63. Pandini G, Vigneri R, Costantino A et al.: Insulin and insulin-like growth factor-I (IGF-I) receptor overexpression in breast cancers leads to insulin/IGF-I hybrid receptor overexpression: evidence for a second mechanism of IGF-I signaling. Clin. Cancer Res. 5, 1935-1944 (1999).
64. Sachdev D, Yee D: Inhibitors of insulin-like growth factor signaling: a therapeutic approach for breast cancer. J. Mammary Gland Biol. Neoplasia 11, 27-39 (2006). (Pubitemid 44309187)
65. Arteaga CL, Kitten LJ, Coronado EB et al.: Blockade of the type I somatomedin receptor inhibits growth of human breast cancer cells in athymic mice. J. Clin. Invest. 84, 1418-1423 (1989).
66. Salatino M, Schillaci R, Proietti CJ et al.: Inhibition of in vivo breast cancer growth by antisense oligodeoxynucleotides to type I insulin-like growth factor receptor mRNA involves inactivation of ErbBs, PI-3K/ Akt and p42/p44 MAPK signaling pathways but not modulation of progesterone receptor activity. Oncogene 23, 5161-5174 (2004).
67. Bonneterre J, Peyrat JP, Beuscart R, Demaille A: Prognostic significance of insulin-like growth factor 1 receptors in human breast cancer. Cancer Res. 50, 6931-6935 (1990).
68. Peyrat JP, Bonneterre J, Beuscart R, Djiane J, Demaille A: Insulin-like growth factor 1 receptors in human breast cancer and their relation to estradiol and progesterone receptors. Cancer Res. 48, 6429-6433 (1988).
69. Law JH, Habibi G, Hu K et al.: Phosphorylated insulin-like growth factor-i/insulin receptor is present in all breast cancer subtypes and is related to poor survival. Cancer Res. 68, 10238-10246 (2008).
70. Mimeault M, Hauke R, Mehta PP, Batra SK: Recent advances in cancer stem/progenitor cell research: therapeutic implications for overcoming resistance to the most aggressive cancers. J. Cell. Mol. Med. 11, 981-1011 (2007).
71. Creighton CJ, Li X, Landis M et al.: Residual breast cancers after conventional therapy display mesenchymal as well as tumorinitiating features. Proc. Natl Acad. Sci. USA 106, 13820-13825 (2009).
72. Li X, Lewis MT, Huang J et al.: Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J. Natl Cancer Inst. 100, 672-679 (2008).
73. Zhou J, Wulfkuhle J, Zhang H et al.: Activation of the PTEN/mTOR/STAT3 pathway in breast cancer stem-like cells is required for viability and maintenance. Proc. Natl Acad. Sci. USA 104, 16158-16163 (2007).
74. Katoh M: Networking of WNT, FGF, Notch, BMP, and Hedgehog signaling pathways during carcinogenesis. Stem Cell Rev. 3, 30-38 (2007).
75. Wang Z, Li Y, Banerjee S, Sarkar FH: Exploitation of the Notch signaling pathway as a novel target for cancer therapy. Anticancer Res. 28, 3621-3630 (2008).
76. Barginear MF, Leung M, Budman DR: The hedgehog pathway as a therapeutic target for treatment of breast cancer. Breast Cancer Res. Treat. 116, 239-246 (2009).
77. Wishart GC, Bissett D, Paul J et al.: Quinidine as a resistance modulator of epirubicin in advanced breast cancer: mature results of a placebo-controlled randomized trial. J. Clin. Oncol. 12, 1771-1777 (1994).
78. Belpomme D, Gauthier S, Pujade-Lauraine E et al.: Verapamil increases the survival of patients with anthracycline-resistant metastatic breast carcinoma. Ann. Oncol. 11, 1471-1476 (2000).
79. Greenberg PL, Lee SJ, Advani R et al.: Mitoxantrone, etoposide, and cytarabine with or without valspodar in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome: a Phase III trial (E2995). J. Clin. Oncol. 22, 1078-1086 (2004).
80. Sandler A, Gordon M, De Alwis DP et al.: A Phase I trial of a potent P-glycoprotein inhibitor, zosuquidar trihydrochloride (LY335979), administered intravenously in combination with doxorubicin in patients with advanced malignancy. Clin. Cancer Res. 10, 3265-3272 (2004).
81. Ruff P, Vorobiof DA, Jordaan JP et al.: A randomized, placebo-controlled, double-blind Phase 2 study of docetaxel compared to docetaxel plus zosuquidar (LY335979) in women with metastatic or locally recurrent breast cancer who have received one prior chemotherapy regimen. Cancer Chemother. Pharmacol. 64, 763-768 (2009).
82. Thomas E, Tabernero J, Fornier M et al.: Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in patients with taxane-resistant metastatic breast cancer. J. Clin. Oncol. 25, 3399-3406 (2007).
83. Perez EA, Lerzo G, Pivot X et al.: Efficacy and safety of ixabepilone (BMS-247550) in a Phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine. J. Clin. Oncol. 25, 3407-3414 (2007).
84. Moulder SL: Ixabepilone for the treatment of taxane-refractory breast cancer. Future Oncol. 4, 333-340 (2008).
85. Letai AG: Diagnosing and exploiting cancers addiction to blocks in apoptosis. Nature Rev. 8, 121-132 (2008).
86. Chan S, Scheulen ME, Johnston S et al.: Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer. J. Clin. Oncol. 23, 5314-5322 (2005).
87. Chollet P, Abrial C, Tacca O et al.: Mammalian target of rapamycin inhibitors in combination with letrozole in breast cancer. Clin. Breast Cancer 7, 336-338 (2006).
88. Baselga J, Fumoleau,P, Gil,M et al.: Phase II three-arm study of CCI-779 in combination with letrozole in postmenopausal women with locally advanced or metastatic breast cancer: preliminary results. Proc. Annu. Meet. Am. Soc. Clin. Oncol. 22(14S), Abstract 544 (2004).
89. Von Hoff DD, LoRusso PM, Rudin CM et al.: Inhibition of the hedgehog pathway in advanced basal-cell carcinoma. N. Engl. J. Med. 361, 1164-1172 (2009).